Vascular smooth muscle cell phenotypic changes in patients with marfan syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 4, 2015, Pages 960-972

  Crosas Molist, Eva ^a,h   Meirelles, Thayna ^g   López Luque, Judit ^h   Serra Peinado, Carla ^a   Selva, Javier ^a   Caja, Laia ^h   Gorbenko Del Blanco, Darya ^a   Uriarte, Juan José ^b   Bertran, Esther ^h   Mendizábal, Yolanda ^a   Hernández, Vanessa ^a   García Calero, Carolina ^h   Busnadiego, Oscar ⁱ   Condom, Enric ^a,h   Toral, David ^h   Castellà, Manel ^d,j   Forteza, Alberto ^k   Navajas, Daniel ^b,f   Sarri, Elisabet ^a   Rodríguez Pascual, Fernando ⁱ   Dietz, Harry C ^l   Fabregat, Isabel ^c,h   Egea, Gustavo ^a,d,e   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b Departments of Physiological Sciences i   (Spain)

^c Physiological Sciences II   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e CATALAN INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY ICN2   (Spain)

^f INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

actin; aortic aneurysms; aortic stiffness; extracellular matrix; focal adhesion; myocardin; RhoA; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALPONIN; CALPONIN 1; COLLAGEN TYPE 1; MYOCARDIN; MYOSIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMOOTHELIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSGELIN; UNCLASSIFIED DRUG; ACTA2 PROTEIN, HUMAN; ACTIN; ACTIN BINDING PROTEIN; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CYTOSKELETON PROTEIN; MUSCLE PROTEIN; NUCLEAR PROTEIN; RHOA PROTEIN, HUMAN; SMTN PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

AORTA ANEURYSM; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; FOCAL ADHESION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MARFAN SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STRESS FIBER; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; AORTA; AORTIC ANEURYSM; CASE CONTROL STUDY; COMPLICATION; LESIONS AND DEFECTS; METABOLISM; PATHOLOGY; SMOOTH MUSCLE FIBER; TUMOR CELL LINE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE;

ACTINS; AORTA; AORTIC ANEURYSM; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLLAGEN TYPE I; CYTOSKELETAL PROTEINS; DILATATION, PATHOLOGIC; FOCAL ADHESIONS; HUMANS; MARFAN SYNDROME; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR PROTEINS; PHENOTYPE; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; STRESS FIBERS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR REMODELING;

EID: 84930239722     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304412     Document Type: Article

References (74)

1. Judge DP, Dietz HC. Marfan's syndrome. Lancet. 2005;366:1965-1976. doi: 10.1016/S0140-6736(05)67789-6.
2. Doyle JJ, Gerber EE, Dietz HC. Matrix-dependent perturbation of TGFβ signaling and disease. FEBS Lett. 2012;586:2003-2015. doi: 10.1016/j. febslet.2012.05.027.
3. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121. doi: 10.1126/science.1124287.
4. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011;332:361-365. doi: 10.1126/science.1192152.
5. Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332:358-361. doi: 10.1126/science.1192149.
6. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801. doi: 10.1152/physrev.00041.2003.
7. Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;15:100-108.
8. Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13-40. doi: 10.1146/ annurev-physiol-012110-142315.
9. van Eys GJ, Niessen PM, Rensen SS. Smoothelin in vascular smooth muscle cells. Trends Cardiovasc Med. 2007;17:26-30. doi: 10.1016/j. tcm.2006.11.001.
10. Owens GK, Geisterfer AA, Yang YW, Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol. 1988;107:771-780.
11. Dong LH, Lv P, Han M. Roles of SM22α in cellular plasticity and vascular diseases. Cardiovasc Hematol Disord Drug Targets. 2012;12:119-125.
12. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8:857-869. doi: 10.1038/nrm2262.
13. Riha GM, Lin PH, Lumsden AB, Yao Q, Chen C. Roles of hemodynamic forces in vascular cell differentiation. Ann Biomed Eng. 2005;33:772-779.
14. Kawai-Kowase K, Owens GK. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol. 2007;292:C59-C69. doi: 10.1152/ajpcell.00394.2006.
15. Sung HJ, Eskin SG, Sakurai Y, Yee A, Kataoka N, McIntire LV. Oxidative stress produced with cell migration increases synthetic phenotype of vascular smooth muscle cells. Ann Biomed Eng. 2005;33:1546-1554. doi: 10.1007/s10439-005-7545-2.
16. O'Callaghan CJ, Williams B. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGFbeta( 1). Hypertension. 2000;36:319-324.
17. Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem. 2007;282:37244-37255. doi: 10.1074/jbc.M708137200.
18. Wang X, Hu G, Betts C, Harmon EY, Keller RS, Van De Water L, Zhou J. Transforming growth factor-β1-induced transcript 1 protein, a novel marker for smooth muscle contractile phenotype, is regulated by serum response factor/myocardin protein. J Biol Chem. 2011;286:41589-41599. doi: 10.1074/jbc.M111.250878.
19. Suwanabol PA, Seedial SM, Shi X, Zhang F, Yamanouchi D, Roenneburg D, Liu B, Kent KC. Transforming growth factor-β increases vascular smooth muscle cell proliferation through the Smad3 and extracellular signal-regulated kinase mitogen-activated protein kinases pathways. J Vasc Surg. 2012;56:446-454. doi: 10.1016/j.jvs.2011.12.038.
20. Koyama N, Koshikawa T, Morisaki N, Saito Y, Yoshida S. Bifunctional effects of transforming growth factor-beta on migration of cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1990;169:725-729.
21. Petzelbauer E, Springhorn JP, Tucker AM, Madri JA. Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-beta 1. Am J Pathol. 1996;149:923-931.
22. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg. 2007;45 Suppl A:A25-A32. doi: 10.1016/j.jvs.2007.03.001.
23. Ailawadi G, Moehle CW, Pei H, Walton SP, Yang Z, Kron IL, Lau CL, Owens GK. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg. 2009;138:1392-1399. doi: 10.1016/j.jtcvs.2009.07.075.
24. Inamoto S, Kwartler CS, Lafont AL, et al. TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. Cardiovasc Res. 2010;88:520-529. doi: 10.1093/ cvr/cvq230.
25. Branchetti E, Poggio P, Sainger R, Shang E, Grau JB, Jackson BM, Lai EK, Parmacek MS, Gorman RC, Gorman JH, Bavaria JE, Ferrari G. Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. Cardiovasc Res. 2013;100:316-324. doi: 10.1093/cvr/cvt205.
26. Zhang J, Wang L, Fu W, Wang C, Guo D, Jiang J, Wang Y. Smooth muscle cell phenotypic diversity between dissected and unaffected thoracic aortic media. J Cardiovasc Surg (Torino). 2013;54:511-521.
27. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996;62:417-426. doi: 10.1002/ (SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R.
28. Caja L, Sancho P, Bertran E, Fabregat I. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells. J Hepatol. 2011;55:351-358. doi: 10.1016/j.jhep.2010.10.041.
29. Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK, Parmacek MS. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol Cell Biol. 2003;23:2425-2437.
30. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8:970-982. doi: 10.1038/nrm2297.
31. Hinson JS, Medlin MD, Lockman K, Taylor JM, Mack CP. Smooth muscle cell-specific transcription is regulated by nuclear localization of the myocardin-related transcription factors. Am J Physiol Heart Circ Physiol. 2007;292:H1170-H1180. doi: 10.1152/ajpheart.00864.2006.
32. Qiu H, Zhu Y, Sun Z, Trzeciakowski JP, Gansner M, Depre C, Resuello RR, Natividad FF, Hunter WC, Genin GM, Elson EL, Vatner DE, Meininger GA, Vatner SF. Short communication: vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with aging. Circ Res. 2010;107:615-619. doi: 10.1161/CIRCRESAHA.110.221846.
33. Saphirstein RJ, Gao YZ, Jensen MH, Gallant CM, Vetterkind S, Moore JR, Morgan KG. The focal adhesion: A regulated component of aortic stiffness. PLoS One. 2013;8:e62461. doi: 10.1371/journal.pone.0062461.
34. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407-411. doi: 10.1038/ng1116.
35. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. TGFbeta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114:1586-1592. doi: 10.1172/ JCI22715.
36. Gomez D, Al Haj Zen A, Borges LF, Philippe M, Gutierrez PS, Jondeau G, Michel JB, Vranckx R. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol. 2009;218:131-142. doi: 10.1002/path.2516.
37. Nataatmadja M, West J, Prabowo S, West M. Angiotensin II Receptor Antagonism Reduces Transforming Growth Factor Beta and Smad Signaling in Thoracic Aortic Aneurysm. Ochsner J. 2013;13:42-48.
38. Worth NF, Rolfe BE, Song J, Campbell GR. Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins. Cell Motil Cytoskeleton. 2001;49:130-145. doi: 10.1002/cm.1027.
39. Fukui D, Miyagawa S, Soeda J, Tanaka K, Urayama H, Kawasaki S. Overexpression of transforming growth factor beta1 in smooth muscle cells of human abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2003;25:540-545. doi: 10.1053/ejvs.2002.1857.
40. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM. Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol. 2007;176:355-367. doi: 10.1083/jcb.200608167.
41. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibrilassociated protein. J Biol Chem. 2003;278:2750-2757. doi: 10.1074/jbc. M209256200.
42. Gomez D, Coyet A, Ollivier V, Jeunemaitre X, Jondeau G, Michel JB, Vranckx R. Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res. 2011;89:446-456. doi: 10.1093/cvr/cvq291.
43. Gomez D, Kessler K, Michel JB, Vranckx R. Modifications of chromatin dynamics control Smad2 pathway activation in aneurysmal smooth muscle cells. Circ Res. 2013;113:881-890. doi: 10.1161/ CIRCRESAHA.113.301989.
44. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res. 2006;98:1032-1039. doi: 10.1161/01.RES.0000218782.52610.dc.
45. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, De Wever O, Mareel M, Gabbiani G. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180:1340-1355. doi: 10.1016/j.ajpath.2012.02.004.
46. Long X, Miano JM. Transforming growth factor-beta1 (TGF-beta1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem. 2011;286:30119-30129. doi: 10.1074/jbc.M111.258814.
47. Wang J, Yan CH, Li Y, Xu K, Tian XX, Peng CF, Tao J, Sun MY, Han YL. MicroRNA-31 controls phenotypic modulation of human vascular smooth muscle cells by regulating its target gene cellular repressor of E1A-stimulated genes. Exp Cell Res. 2013;319:1165-1175. doi: 10.1016/j. yexcr.2013.03.010.
48. Li P, Zhu N, Yi B, Wang N, Chen M, You X, Zhao X, Solomides CC, Qin Y, Sun J. MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ Res. 2013;113:1117-1127. doi: 10.1161/CIRCRESAHA.113.301306.
49. Zheng XL. Myocardin and smooth muscle differentiation. Arch Biochem Biophys. 2014;543:48-56. doi: 10.1016/j.abb.2013.12.015.
50. Qiu P, Ritchie RP, Fu Z, Cao D, Cumming J, Miano JM, Wang DZ, Li HJ, Li L. Myocardin enhances Smad3-mediated transforming growth factorbeta1 signaling in a CArG box-independent manner: Smad-binding element is an important cis element for SM22alpha transcription in vivo. Circ Res. 2005;97:983-991. doi: 10.1161/01.RES.0000190604.90049.71.
51. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210. doi: 10.1002/path.2277.
52. Della Corte A, Quarto C, Bancone C, Castaldo C, Di Meglio F, Nurzynska D, De Santo LS, De Feo M, Scardone M, Montagnani S, Cotrufo M. Spatiotemporal patterns of smooth muscle cell changes in ascending aortic dilatation with bicuspid and tricuspid aortic valve stenosis: focus on cell-matrix signaling. J Thorac Cardiovasc Surg. 2008;135:8-18, 18.e1. doi: 10.1016/j.jtcvs.2007.09.009.
53. He R, Guo DC, Estrera AL, Safi HJ, Huynh TT, Yin Z, Cao SN, Lin J, Kurian T, Buja LM, Geng YJ, Milewicz DM. Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections. J Thorac Cardiovasc Surg. 2006;131:671-678. doi: 10.1016/j.jtcvs.2005.09.018.
54. Nataatmadja M, West J, West M. Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm. Circulation. 2006;114(1 Suppl):I371-I377. doi: 10.1161/CIRCULATIONAHA.105.000927.
55. Adams JN, Brooks M, Redpath TW, Smith FW, Dean J, Gray J, Walton S, Trent RJ. Aortic distensibility and stiffness index measured by magnetic resonance imaging in patients with Marfan's syndrome. Br Heart J. 1995;73:265-269.
56. Groenink M, de Roos A, Mulder BJ, Spaan JA, van der Wall EE. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol. 1998;82:203-208.
57. Nollen GJ, Groenink M, Tijssen JG, Van Der Wall EE, Mulder BJ. Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J. 2004;25:1146-1152. doi: 10.1016/j. ehj.2004.04.033.
58. Hirata K, Triposkiadis F, Sparks E, Bowen J, Wooley CF, Boudoulas H. The Marfan syndrome: abnormal aortic elastic properties. J Am Coll Cardiol. 1991;18:57-63.
59. de Wit A, Vis K, Jeremy RW. Aortic stiffness in heritable aortopathies: relationship to aneurysm growth rate. Heart Lung Circ. 2013;22:3-11. doi: 10.1016/j.hlc.2012.08.049.
60. Humphrey JD, Milewicz DM, Tellides G, Schwartz MA. Cell biology. Dysfunctional mechanosensing in aneurysms. Science. 2014;344:477-479. doi: 10.1126/science.1253026.
61. Gittenberger-de Groot AC, DeRuiter MC, Bergwerff M, Poelmann RE. Smooth muscle cell origin and its relation to heterogeneity in development and disease. Arterioscler. Thromb. Vasc. Biol. 1999; 19:1589-1594.
62. Bunton TE, Biery NJ, Myers L, Gayraud B, Ramirez F, Dietz HC. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res. 2001;88:37-43.
63. Pilop C, Aregger F, Gorman RC, Brunisholz R, Gerrits B, Schaffner T, Gorman JH III, Matyas G, Carrel T, Frey BM. Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation. 2009;120:983-991. doi: 10.1161/ CIRCULATIONAHA.108.843516.
64. Kim HR, Appel S, Vetterkind S, Gangopadhyay SS, Morgan KG. Smooth muscle signalling pathways in health and disease. J Cell Mol Med. 2008;12(6A):2165-2180. doi: 10.1111/j.1582-4934.2008.00552.x.
65. Gerthoffer WT, Gunst SJ. Invited review: focal adhesion and small heat shock proteins in the regulation of actin remodeling and contractility in smooth muscle. J Appl Physiol (1985). 2001;91:963-972.
66. Sehgel NL, Zhu Y, Sun Z, Trzeciakowski JP, Hong Z, Hunter WC, Vatner DE, Meininger GA, Vatner SF. Increased vascular smooth muscle cell stiffness: A novel mechanism for aortic stiffness in hypertension. Am J Physiol Heart Circ Physiol. 2013;305:H1281-H1287. doi: 10.1152/ ajpheart.00232.2013.
67. Bi D, Nishimura J, Niiro N, Hirano K, Kanaide H. Contractile properties of the cultured vascular smooth muscle cells: The crucial role played by RhoA in the regulation of contractility. Circ Res. 2005;96:890-897. doi: 10.1161/01.RES.0000163018.66460.85.
68. Chen S, Crawford M, Day RM, Briones VR, Leader JE, Jose PA, Lechleider RJ. RhoA modulates Smad signaling during transforming growth factor-beta-induced smooth muscle differentiation. J Biol Chem. 2006;281:1765-1770. doi: 10.1074/jbc.M507771200.
69. Zhang W, Huang Y, Gunst SJ. The small GTPase RhoA regulates the contraction of smooth muscle tissues by catalyzing the assembly of cytoskeletal signaling complexes at membrane adhesion sites. J Biol Chem. 2012;287:33996-34008. doi: 10.1074/jbc.M112.369603.
70. Bee KJ, Wilkes DC, Devereux RB, Basson CT, Hatcher CJ. TGFβRIIb mutations trigger aortic aneurysm pathogenesis by altering transforming growth factor β2 signal transduction. Circ Cardiovasc Genet. 2012;5:621-629. doi: 10.1161/CIRCGENETICS.112.964064.
71. Renard M, Callewaert B, Baetens M, et al. Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in FTAAD. Int J Cardiol. 2013;165:314-321. doi: 10.1016/j.ijcard.2011.08.079.
72. Gillis E, Van Laer L, Loeys BL. Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-β signaling and vascular smooth muscle cell contractility. Circ Res. 2013;113:327-340. doi: 10.1161/CIRCRESAHA.113.300675.
73. Teixido-Tura G, Redheuil A, Rodríguez-Palomares J, Gutiérrez L, Sánchez V, Forteza A, Lima JA, García-Dorado D, Evangelista A. Aortic biomechanics by magnetic resonance: early markers of aortic disease in Marfan syndrome regardless of aortic dilatation? Int J Cardiol. 2014;171:56-61. doi: 10.1016/j.ijcard.2013.11.044.
74. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev. 2009;89:957-989. doi: 10.1152/physrev.00041.2008.